{
    "clinical_study": {
        "@rank": "33719", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who\n      have refractory or recurrent endometrial cancer."
        }, 
        "brief_title": "Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer", 
        "condition": "Endometrial Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Endometrial Neoplasms", 
                "Sarcoma, Endometrial Stromal", 
                "Cystadenocarcinoma, Serous"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the therapeutic activity of paclitaxel in patients with refractory or\n           recurrent endometrial papillary carcinoma.\n\n        -  Determine the objective response and duration of response in patients treated with this\n           regimen.\n\n        -  Determine the acute side effects of this regimen in these patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks in the\n      absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 12 weeks.\n\n      PROJECTED ACCRUAL: Approximately 16-29 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed endometrial papillary carcinoma (uterine papillary serous\n             carcinoma)\n\n               -  Progressive or recurrent\n\n          -  Bidimensionally measurable disease\n\n          -  Platinum refractory disease, defined by one of the following:\n\n               -  Progression during platinum-based chemotherapy\n\n               -  Stable disease for at least 4 courses of platinum-based chemotherapy\n\n               -  Recurrence within 4 months of platinum-based chemotherapy\n\n          -  No brain involvement or leptomeningeal disease\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  75 and under\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Neutrophil count at least 1,500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 50 umol/L\n\n        Renal:\n\n          -  BUN no greater than 8.0 mmol/L\n\n          -  Creatinine no greater than 120 umol/L\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Other:\n\n          -  Not pregnant\n\n          -  Fertile patients must use effective contraception\n\n          -  HIV negative\n\n          -  No other prior or concurrent malignancy except basal cell carcinoma of the skin\n\n          -  No active bacterial infection (e.g., urinary tract infection)\n\n          -  No uncontrolled or potentially active site of infection (e.g., fistula or abscess)\n\n          -  No psychological, familial, sociological, or geographical condition that would\n             preclude study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior chemotherapy\n\n          -  At least 1 prior platinum containing regimen\n\n          -  At least 50 mg/m2 per course for a maximum of 28 days for cisplatin\n\n          -  At least 5 times AUC for a maximum of 4 weeks per course for carboplatin\n\n          -  Prior non-taxane-containing chemotherapy allowed\n\n        Endocrine therapy:\n\n          -  At least 4 weeks since prior hormonal therapy\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  At least 3 months since prior radiotherapy to target lesion\n\n          -  Concurrent radiotherapy allowed for bone pain provided evaluable lesions are outside\n             of irradiation field)\n\n        Surgery:\n\n          -  Prior surgical management of lymph nodes allowed"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "August 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00022620", 
            "org_study_id": "EORTC-55961", 
            "secondary_id": "EORTC-55961"
        }, 
        "intervention": {
            "intervention_name": "paclitaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "keyword": [
            "recurrent endometrial carcinoma", 
            "endometrial papillary serous carcinoma"
        ], 
        "lastchanged_date": "September 20, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/EORTC-55961"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }, 
                    "name": "Allgemeines Krankenhaus der Stadt Wien"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "B-2650"
                    }, 
                    "name": "Universitair Ziekenhuis Antwerpen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10128"
                    }, 
                    "name": "Ospedale Mauriziano Umberto I"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voghera (PV)", 
                        "country": "Italy", 
                        "zip": "27058"
                    }, 
                    "name": "Ospedale Civile"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coimbra", 
                        "country": "Portugal", 
                        "zip": "3049"
                    }, 
                    "name": "Hospitais da Universidade de Coimbra (HUC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Hospital Universitasrio San Carlos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gateshead", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "NE9 6SX"
                    }, 
                    "name": "Queen Elizabeth Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Belgium", 
                "Italy", 
                "Portugal", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "official_title": "Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC)", 
        "overall_official": {
            "affiliation": "Allgemeines Krankenhaus - Universitatskliniken", 
            "last_name": "Gerald Gitsch, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2002", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00022620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "European Organisation for Research and Treatment of Cancer - EORTC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "European Organisation for Research and Treatment of Cancer - EORTC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "Allgemeines Krankenhaus der Stadt Wien": "48.208 16.374", 
        "Hospitais da Universidade de Coimbra (HUC)": "40.211 -8.429", 
        "Hospital Universitasrio San Carlos": "40.417 -3.7", 
        "Ospedale Civile": "44.992 9.01", 
        "Ospedale Mauriziano Umberto I": "45.071 7.684", 
        "Queen Elizabeth Hospital": "54.953 -1.603", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitair Ziekenhuis Antwerpen": "51.153 4.438"
    }
}